The performance of companies tied to Sildenafil's legacy presents a complex investment landscape. While the initial success generated substantial returns , generic competition have significantly eroded sales . Investing in related pharmaceutical firms now requires a thorough assessment of intellectual property protection , evolving medical shifts ,